BioNTech (Mfg Services) vs Corden Pharma: CDMO Comparison
Side-by-side comparison of BioNTech (Mfg Services) and Corden Pharma on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Corden Pharma has FDA inspections on record (2); BioNTech (Mfg Services) does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- BioNTech (Mfg Services) appears as a manufacturing partner on more matched clinical programs (24 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both BioNTech (Mfg Services) and Corden Pharma qualify as mRNA/LNP manufacturers; BioNTech (Mfg Services) carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both BioNTech (Mfg Services) and Corden Pharma qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: BioNTech (Mfg Services) vs Corden Pharma
Which has the stronger FDA inspection record, BioNTech (Mfg Services) or Corden Pharma?
Both BioNTech (Mfg Services) and Corden Pharma maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioNTech (Mfg Services) has 0 FDA inspections on record; Corden Pharma has 2.
How do BioNTech (Mfg Services) and Corden Pharma compare on European GMP coverage?
BioNTech (Mfg Services) holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. Corden Pharma holds 9 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — BioNTech (Mfg Services) or Corden Pharma?
BioNTech (Mfg Services) is matched to 24 ClinicalTrials.gov records as a manufacturing partner; Corden Pharma is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for mRNA/LNP manufacturing — BioNTech (Mfg Services) or Corden Pharma?
Both BioNTech (Mfg Services) and Corden Pharma are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BioNTech (Mfg Services) carries a Signal Score of 85/100 and Corden Pharma carries 82/100 — essentially tied for BioNTech (Mfg Services). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →